Skip to main content
SBER21/AER21 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Pre-Reg Required
Pre-Reg Required
New for 2020
New for 2020
CSP Icon
CSP Icon
Livestreaming Session Icon
Livestreaming Session Icon
On-Demand Session
On-Demand Session
CIP Accredited
CIP Accredited
Additional Fee
Additional Fee
Poster Icons
Record Session Icon
Record Session Icon
Pre-Reg Required
Pre-Reg Required
New for 2020
New for 2020
Part I/II
Part I/II
CSP Icon
CSP Icon
Livestreaming Session Icon
Livestreaming Session Icon
Prerecorded Session Icon
Prerecorded Session Icon
CIP Accredited
CIP Accredited
Pillars Icon
Pillars Icon

2021 AER Conference

Pharma/Biotech Perspectives Track

Research Involving Data and Biospecimens Track

C02 - Is Your Institution Ready to Conduct Human Gene Therapy Research?

Thursday, November 18, 2021
11:30 AM - 12:30 PM ET
Location: Livestreamed
New for 2020 CSP Icon Livestreaming Session Icon CIP Accredited
This session is designed for those who are new to IBC/gene therapy or whose hospital/health system was thrust into this space by COVID-19. The world has been introduced to mRNA and was surprisingly comfortable with genetically engineered treatments. Gene therapy-based products are entering human trials at an exponential growth rate. During this session, speakers will review the basics of conducting human gene therapy research and the requirements for IBC review as outlined in NIH Office of Science Policy guidelines.

Learning Objectives:

  • Review the basic regulations and guidelines governing IBCs and gene therapy research
  • Explain the role of the IBC and where their oversight is different from the IRB
  • Share key takeaways to prepare your research organization to participate in this growing field of research